Navigation Links
SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
Date:10/14/2008

ide important additional information for doctors as they evaluate treatment options for complex coronary patients," said Keith Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "The comparable safety and efficacy outcomes with PCI and CABG in patients with left main disease in this trial indicate PCI is a good treatment alternative for this patient population. Physicians will also be able to consider the SYNTAX Score analysis, demonstrating no difference in safety and efficacy outcomes between PCI and CABG in approximately two-thirds of the SYNTAX patient population, when assessing the appropriate treatment for their patients."

The SYNTAX Score is breaking new ground by scientifically defining a new measure for anatomical complexity that seeks to provide guidance to physicians on optimal treatment options for this high-risk group of patients. The SYNTAX Score characterizes coronary anatomy based on lesion frequency, complexity and location, relying on data from the SYNTAX trial, and assigns a score to each patient. The analysis of the raw SYNTAX Score data presented today demonstrated that PCI and CABG patients whose scores fell into the lower or intermediate terciles of complexity had similar rates of MACCE (Major Adverse Cardiovascular or Cerebrovascular Event rate, including all-cause death, stroke, MI and repeat revascularization) at 12 months. For patients whose SYNTAX Score fell into the upper tercile -- those with the greatest lesion complexity -- there was a significant increase in MACCE for PCI patients compared with CABG patients.

The 12-month subset results for patients with left main disease reported comparable rates of overall MACCE for the CABG group and the PCI group (13.6 percent for CABG versus 15.8 percent for PCI, p=0.44), as well as similar overall safety outcomes (death, stroke, MI) for the two groups (9.1 percent for CABG versus 7.0 percent for PCI, p=0.29). As expected, the rate of revascularization was signifi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
2. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
3. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
6. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
7. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
8. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
9. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
10. New Studies Confirm Safety, Effectiveness of Balloon Sinuplasty(TM) Technology for Chronic Sinusitis
11. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Calif. , Aug. 27, 2015 DURECT ... is scheduled to present at three upcoming healthcare conferences.  ... President and CEO, will present at the Rodman & ... a.m. Eastern time. The conference is being held at ... City . A live audio webcast of the ...
(Date:8/27/2015)... 27, 2015  Eli Lilly and Company (NYSE: ... Conference on Thursday, September 17, 2015. Sue Mahony ... Oncology and Richard Gaynor , M.D., senior vice ... Oncology, will participate in a fireside chat at 3:30 ... audio webcast will be available on the "Webcasts & ...
(Date:8/27/2015)... Ga. , Aug. 27, 2015  MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected ... therapies for the Wound Care, Surgical, Orthopedic, Spine, ... responded today and corrected the multiple inaccuracies in ... Foundation ("MTF") regarding the recent rulings from the ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly ... for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, ... track product movement from beginning to end. , Businesses benefit greatly from having the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... Rochester, NY (PRWEB) , ... August 28, 2015 , ... ... injectable, Kybella™. It is the first and only nonsurgical product approved by the ... Dr. Vito Quatela and Dr. William Koenig are among ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... CEPH ) announced today that the underwriters ... aggregate principal amount of 2.50% convertible senior subordinated notes ... to purchase $65 million of additional notes, bringing the ... $500 million. Completion of the notes offering, including the ...
... Ontario Systems, a leading provider of revenue cycle ... management and health care industries, today announced that ... the company and will lead its debt management ... direction of all Ontario debt management solutions, including ...
... tied to this nutritional deficit , , FRIDAY, May ... may contribute to cancer development, U.S. researchers have found. ... communication among cells due to, among other things, low ... an epidemiologist at the Moores Cancer Center at the ...
... findings could alter treatment methods, , , THURSDAY, May 21 (HealthDay ... amputated because of diabetes were reduced by 36 percent when ... to lower their blood fat levels, new research has found. ... who took either 200 milligrams of fenofibrate or a placebo ...
... Patients under 44 were three times more likely to die, ... Younger men diagnosed with advanced prostate cancer don,t live as ... study finds. , "Overall, young men with prostate cancer do ... prostate cancers did substantially worse than old men with similar ...
... May 22 The National Board of Certification for ... performance exam that will be part of the testing ... weeks, 300 interpreters will "test the test" designed to ... and skills in real-life medical interpreting scenarios. This process ...
Cached Medicine News:Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 2Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 3Health News:Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes 4Health News:Cutler to Direct Debt Management Product Strategy at Ontario Systems 2Health News:Drug May Lessen Amputation Risk for Diabetics 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 2Health News:Advanced Prostate Cancer Deadlier in Younger Men 3Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 2Health News:National Medical Interpreter Certification Testing Enters Pilot Phase 3
Desmarres Lid Retractor thin solid blades. Size 2....
... of the AMO Prestige System marked ... The combination of safety with high-performance ... of fluidic conditions in the in ... Pump" orchestrates the reaction and interaction ...
Highly versatile, efficient, compact and accurate digital readout display....
... phaco system has all the features of ... dependable engineering means minimal maintenance. Small, light ... site to site. Lowest cost reusable tubing ... No longer is there a price objection ...
Medicine Products: